Janux Therapeutics

Janux Therapeutics

Biotechnology
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

$616.7M

Market Cap • 11/20/2026

2017

(9 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,7

P/S

26,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

14,9

EPS

—

Market Cap

Market Cap

616,7M

EV

-308,6M

EV/Revenue

-13,3

EV/EBITDA

2,2

EV/EBIT

2,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1,6%

Total Yield

-1,6%

Payout

0%

Retained Earnings

-419,3M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

514,9%

Capex/Revenue

2,5%

Capex/D&A

31,4%

Capex/OCF

-1,1%

SBC/OCF

—

% PPE

2%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

63%

CAGR Op. Income 5Y

45,9%

CAGR Net Income 5Y

36,7%

CAGR EPS 5Y

-19,1%

CAGR OCF 5Y

45,8%

Leverage

N.D./EBITDA

6,7

Debt/Equity

0%

Current Ratio

17,7

Quick Ratio

17,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium